Merit Medical Systems

Merit Medical Systems, Inc. engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger, and William Padilla in July 1987 and is headquartered in South Jordan, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merit Medical Systems reports robust Q4 performance and eyes growth

Merit Medical Systems delivered a strong Q4 performance with revenue growth, increased gross profit, and exceeding net income expectations.
While facing challenges in certain segments and regulatory compliance, the company remains optimistic about growth opportunities and operational improvements.
Strategic pricing initiatives and a focus on achieving financial targets position Merit Medical for continued success and potential expansion through M&A activities.
The company's commitment to discipline, prioritization, and operational excellence underscores its resilience and potential for sustained growth in the future.

Merit Medical Systems posts strong Q1 results, eyes debt reduction

Merit Medical Systems delivered robust financial results in Q1 2023, showcasing growth in revenue, operating income, and net income. The company maintains its financial guidance for 2023, emphasizing a commitment to debt reduction and free cash flow targets. Analyst inquiries highlighted areas for improvement and strategic focus moving forward.

Merit Medical Systems reports robust Q2 earnings amidst strategic acquisitions

Merit Medical Systems delivered strong financial performance in Q2 2023, marked by revenue growth, improved profitability, and strategic acquisitions. While facing challenges in the Endoscopy segment and uncertainties in international markets, the company remains focused on leveraging opportunities in catch-up procedures and strategic M&A for sustainable growth.

Merit Medical Systems excels in Q3, eyes growth opportunities

Merit Medical Systems delivered a strong Q3 performance with notable revenue growth, profit increases, and enhanced net income and EPS.
While facing challenges like margin pressure and regional headwinds, the company remains focused on long-term growth strategies and operational efficiency.
With opportunities for revenue expansion, product advancements, and margin improvements on the horizon, Merit Medical Systems is poised for continued success and shareholder value creation.

Merit Medical Systems excels in Q4 2023, eyes strategic growth

Merit Medical Systems delivered strong financial results in Q4 2023, driven by revenue growth and margin expansion.
The company's strategic initiatives and focus on operational efficiency position it well for future growth and profitability.
Challenges such as SKU rationalization and China revenue decline require careful management and strategic planning.
Opportunities in M&A, pricing power initiatives, R&D investments, and gross margin expansion strategies offer avenues for continued success.

Merit Medical Systems excels in Q1, eyes growth opportunities

Merit Medical Systems delivered strong Q1 results with revenue growth and profitability improvements, driven by operational progress and strategic focus on innovation.
While facing challenges such as pricing pressures in China and debt reduction strategies, the company remains poised for growth through new opportunities and market strategies.
With a solid performance in Q1 and positive Q2 guidance, Merit Medical Systems demonstrates resilience and a strategic approach to navigating industry challenges.
The company's commitment to financial stability, innovation, and shareholder value sets a strong foundation for future growth and market competitiveness.

Merit Medical Systems reports robust Q3 results amidst supply challenges

Merit Medical Systems delivered strong financial results in Q3, driven by revenue growth and margin improvement.
The company's strategic acquisition and focus on innovation position it well for future growth despite supply chain disruptions.
Challenges in supply chain management and analyst inquiries highlight areas for ongoing attention and improvement.
Overall, Merit Medical Systems maintains a positive outlook on its performance and growth trajectory.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merit Medical's (MMSI) Q3 earnings gain from higher revenues and solid segmental performance benefit. However, contraction in gross margin remains a concern.

Merit Medical (MMSI) Q3 Earnings & Revenues Miss Estimates

Merit Medical Systems' (MMSI) CEO Fred Lampropoulos on Q3 2019 Results - Earnings Call Transcript

Merit Medical (MMSI) delivered earnings and revenue surprises of -37.78% and -1.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Merit Medical (MMSI) Q3 Earnings and Revenues Lag Estimates

Merit Medical (MMSI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Merit Medical (MMSI) Q3 Earnings Expected to Decline

Merit faces short term headwinds consolidating their acquisitions.

Merit Medical: Revised Guidance Just A Speed Bump

Atrion

Corcept Therapeutics

National Research Corp

Supernus Pharmaceuticals

According to the GuruFocus All-In-One Screener as of Friday, the following health care stocks are popular among gurus.

5 Health Care Stocks - Gurus Are Buying

Shares tank after the company receives an analyst downgrade and an SEC filing reveals that an important insider has been selling.

Why Merit Medical Systems Stock Is Falling Today

SOUTH JORDAN, Utah, Sept.  03, 2019  (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it will participate at four conferences in September.

Merit Medical to Present at Three Conferences in September

Merit Medical (MMSI) reported earnings 30 days ago. What's next for the stock?

Merit Medical (MMSI) Down 37.6% Since Last Earnings Report: Can It Rebound?

SOUTH JORDAN, Utah, Aug.  19, 2019  (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading manufacturer and marketer of proprietary disposable devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy, announced today that it has appointed Lynne N. Ward to serve as an independent director of the Company.

Merit Medical Announces Appointment of Lynne N. Ward to Its Board of Directors

President & CEO of Merit Medical Systems Inc (30-Year Financial, Insider Trades) Fred P Lampropoulos (insider trades) sold 40,000 shares of MMSI on 08/15/2019 at an average price of $36.86 a share.

Merit Medical Systems Inc (MMSI) President & CEO Fred P Lampropoulos Sold $1.5 million of Shares

Comfort Systems USA

W. R. Grace & Co.

Ligand Pharmaceuticals

Everest RE Group

Spirit Airlines

USA Truck

Insiders sell stocks for many reasons, but the only reason they buy is that they believe they will profit. Check out these insider buying picks.

7 Stocks the Insiders Are Buying on Sale

COO of Merit Medical Systems Inc (30-Year Financial, Insider Trades) Ronald Frost (insider trades) bought 5,000 shares of MMSI on 07/30/2019 at an average price of $40 a share.

Merit Medical Systems Inc (MMSI) COO Ronald Frost Bought $200,000 of Shares

Shares fall after the company reports second-quarter results that missed the mark.

Why Merit Medical Systems Is Tanking Today

Higher revenues and solid segmental performance margins benefit Merit Medical's (MMSI) Q2 earnings. However, contraction in both gross and operating margins remains a concern.

Merit Medical (MMSI) Q2 Earnings & Revenues Miss Estimates

Merit Medical Systems, Inc. (MMSI) CEO Fred Lampropoulos on Q2 2019 Results - Earnings Call Transcript

Merit Medical (MMSI) delivered earnings and revenue surprises of -16.00% and -1.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Merit Medical (MMSI) Q2 Earnings and Revenues Miss Estimates

The Brightwater Medical-acquisition broadens Merit Medical's (MMSI) product offerings.

Merit Medical Acquires Brightwater Medical for $35 Million

Acuity Brands

Brunswick

Brady Corporation

Ford Motor Company

Fortune Brands Home & Security

General Motors

Stocks that could be negatively impacted by tariffs on Mexico include: Acuity Brands, Brunswick Corporation, and Fortune Brands.

Analysts are worried these US stocks could take a hit from tariffs on Mexico

Merit Medical Systems has been struggling lately, but the selling pressure may be coming to an end soon.

Merit Medical Systems Sees Hammer Chart Pattern: Time to Buy?

Merit Medical (MMSI) continues to benefit from solid product pipeline, HeRO product line and persistent focus on R&D.

Here's Why You Should Bet on Merit Medical (MMSI) Stock Now

Merit Medical (MMSI) Down 4.4% Since Last Earnings Report: Can It Rebound?

Merit Medical (MMSI) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here is Why Growth Investors Should Buy Merit Medical (MMSI) Now

Higher revenues, solid segmental performance and strong adjusted gross margins benefit Merit Medical's (MMSI) Q1 earnings. However, higher expenses remain a concern.

Merit Medical (MMSI) Q1 Earnings &amp; Revenues Beat Estimates

Merit Medical Systems, Inc. (MMSI) CEO Fred Lampropoulos on Q1 2019 Results - Earnings Call Transcript

News for Merit Medical Systems Stock (MMSI)